Reply to Blot et al. and to Inoue et al..pdf (504.07 kB)
Download fileReply to Blot et al. and to Inoue et al.
journal contribution
posted on 2022-03-09, 17:02 authored by Oliver McElvaney, Natalie McEvoyNatalie McEvoy, Noel G McElvaneyNoel G McElvaney, Gerard CurleyGerard CurleyWe thank Blot and colleagues for their interest in our article and for raising an important question regarding the suitability of IL-6 as a therapeutic target in coronavirus disease (COVID-19).
In their correspondence, Blot and colleagues provide data on IL-6 levels measured in patients with a diagnosis of COVID-19 versus non–COVID-19 pneumonia. Although we believe the data presented by Blot and colleagues are valid, we suggest that the IL-6 levels depicted are, by virtue of sample timing, processing methodology, and patient severity of disease, not comparable to ours and should be interpreted in context.
History
Comments
The original article is available at https://www.atsjournals.org/Published Citation
McElvaney OJ, McEvoy NL, McElvaney NG, Curley GF. Reply to Blot et al. and to Inoue et al. Am J Respir Crit Care Med. 2021;203(1):141-142Publication Date
21 September 2020External DOI
PubMed ID
32955924Department/Unit
- Anaesthetics and Critical Care
- Beaumont Hospital
- Medicine
Publisher
American Thoracic SocietyVersion
- Published Version (Version of Record)
Usage metrics
Keywords
COVID-19CoronavirusSARS-CoV-2PandemicsICUIntensive CareIL-6severitynon–COVID-19 pneumoniacorrespondencecommunity-acquired pneumonia(CAP) groupStreptococcus pneumoniaeRT-PCRhospital admission,disease severityMechanical ventilationinvasive ventilationhyperinflammatory phasebiphasic illnessstudy protocolInfectious DiseasesIntensive CareRespiratory Diseases